Brain

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globallySARASOTA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE)…

5 months ago

Natus introduces autoSCORE, an innovative AI solution capable of a new era of expert-level clinical EEG interpretation

MIDDLETON, Wis., Aug. 7, 2024 /PRNewswire/ -- Natus Medical Incorporated has announced the launch of autoSCORE, the first-of-its-kind artificial intelligence…

5 months ago

LabCentral Launches “The Dish with Johannes” Video Series Profiling Biotech Entrepreneurs and Scientists Shaping the Industry’s Future

CAMBRIDGE, Mass., Aug. 7, 2024 /PRNewswire/ --  LabCentral, the premier Massachusetts-based network of coworking labs designed to accelerate high-potential biotech startups, launched…

5 months ago

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Silo to advance homing peptide development for initial indication in multiple sclerosis SARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) --…

5 months ago

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical…

5 months ago

BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting

August 7, 2024News Release BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting COPENHAGEN, DENMARK and BOSTON, MA,…

5 months ago

Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic…

5 months ago

Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Openextension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food…

5 months ago

New Results from AlzeCure’s Pain Project TrkA-NAM Presented at the Pain Conference IASP 2024

STOCKHOLM, SE / ACCESSWIRE / August 07, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a…

5 months ago

Cryoport Reports Second Quarter 2024 Financial Results

Revenue improved sequentially across all businessesCommercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially A record total…

5 months ago